These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7201835)

  • 41. Differences in pleural fluid characteristics, white cell count and biochemistry of tuberculous and malignant pleural effusions.
    Liam CK; Lim KH; Wong CM
    Med J Malaysia; 2000 Mar; 55(1):21-8. PubMed ID: 11072486
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid.
    van Hensbergen Y; Broxterman HJ; Hanemaaijer R; Jorna AS; van Lent NA; Verheul HM; Pinedo HM; Hoekman K
    Clin Cancer Res; 2002 Dec; 8(12):3747-54. PubMed ID: 12473585
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of route of administration and effusions on methotrexate pharmacokinetics.
    Wan SH; Huffman DH; Azarnoff DL; Stephens R; Hoogstraten B
    Cancer Res; 1974 Dec; 34(12):3487-91. PubMed ID: 4429965
    [No Abstract]   [Full Text] [Related]  

  • 44. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
    Gabizon A; Catane R; Uziely B; Kaufman B; Safra T; Cohen R; Martin F; Huang A; Barenholz Y
    Cancer Res; 1994 Feb; 54(4):987-92. PubMed ID: 8313389
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical significance of soluble interleukin 2 receptor alpha in the pleural fluid].
    Ni SS; Gao ZL
    Zhonghua Jie He He Hu Xi Za Zhi; 1993 Feb; 16(2):81-2, 123. PubMed ID: 8221956
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of acute phase proteins in pleural effusion discrimination.
    Calikoğlu M; Sezer C; Unlü A; Kanik A; Tamer L; Calikoğlu I
    Tuberk Toraks; 2004; 52(2):122-9. PubMed ID: 15241695
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
    Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
    Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
    Li CS; Cheng BC; Ge W; Gao JF
    Int J Clin Pract; 2007 Mar; 61(3):444-8. PubMed ID: 17313612
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum cancer antigen 125 in patients with pleural effusions.
    How SH; Liam CK; Jamalludin AR; Chin SP; Zal AB
    Med J Malaysia; 2006 Dec; 61(5):558-63. PubMed ID: 17623956
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys.
    Arndt CA; Balis FM; McCully CL; Colvin OM; Poplack DG
    Cancer Res; 1988 Apr; 48(8):2113-5. PubMed ID: 3349482
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.
    Gieseler F; Lühr I; Kunze T; Mundhenke C; Maass N; Erhart T; Denker M; Beckmann D; Tiemann M; Schulte C; Dohrmann P; Cavaillé F; Godeau F; Gespach C
    Thromb Haemost; 2007 Jun; 97(6):1023-30. PubMed ID: 17549306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Local therapy of malignant pleural effusions].
    Titscher R; Kokron O; Letnansky K
    Wien Klin Wochenschr; 1973 May; 85(18):338-40. PubMed ID: 4699494
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparative metabolism of 2-[bis(2-chloroethyl)amino]tetrahydro-2-H-1,3,2-oxazaphosphorine-2-oxide (cyclophosphamide) and its enantiomers in humans.
    Jarman M; Milsted RA; Smyth JF; Kinas RW; Pankiewicz K; Stec WJ
    Cancer Res; 1979 Jul; 39(7 Pt 1):2762-7. PubMed ID: 445480
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Chronic nonspecific pleurisy--indication for cytostatic treatment? (AUTHOR'S TRANSL)].
    Matzel W; Knolle H
    Z Erkr Atmungsorgane; 1974; 141(1):51-7. PubMed ID: 4460421
    [No Abstract]   [Full Text] [Related]  

  • 55. Pharmacokinetics of "activated" cyclophosphamide and therapeutic efficacies.
    Voelcker G; Wagner T; Wientzek C; Hohorst HJ
    Cancer; 1984 Sep; 54(6 Suppl):1179-86. PubMed ID: 6467149
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mezlocillin in pleural effusions--analysis by HPLC.
    Knöller J; Schönfeld W; Mayer M; König W
    Zentralbl Bakteriol Mikrobiol Hyg A; 1988 May; 268(3):370-5. PubMed ID: 3407362
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantitation of 4-hydroxycyclophosphamide/aldophosphamide in whole blood.
    Anderson LW; Ludeman SM; Colvin OM; Grochow LB; Strong JM
    J Chromatogr B Biomed Appl; 1995 May; 667(2):247-57. PubMed ID: 7663697
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Cyclophosphamide--alkylating cytostatic. Detection of activated metabolites and pharmacokinetic in tumor patients].
    Wagner T
    Fortschr Med; 1982 Dec; 100(45):2127-30. PubMed ID: 7173798
    [No Abstract]   [Full Text] [Related]  

  • 59. Clinical pharmacology of cyclophosphamide.
    Bagley CM; Bostick FW; DeVita VT
    Cancer Res; 1973 Feb; 33(2):226-33. PubMed ID: 4688880
    [No Abstract]   [Full Text] [Related]  

  • 60. Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test.
    Wagner T; Heydrich D; Jork T; Voelcker G; Hohorst HJ
    J Cancer Res Clin Oncol; 1981; 100(1):95-104. PubMed ID: 7240346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.